Apr. 25 at 12:23 AM
$OSTX
From a microstructure perspective, today’s move suggests supply absorption in the
$1.50–
$1.60 region has likely been partially cleared, with the tape now transitioning into a higher liquidity regime where marginal buyers are competing ahead of binary events.
Against that backdrop, the upcoming biomarker presentation becomes the first of two immediate inflection points. If the dataset is internally consistent—clean endpoint alignment, reproducible signal separation, and coherent subgroup outcomes—then regulatory interpretation risk compresses. That is where advisory-level scientific (Dr. Langer) framing matters: not altering results, but structuring them so FDA-relevant inference is straightforward and low-ambiguity.
In that context, the current action looks less like a finished move and more like pre-catalyst re-pricing. Volume at this level is consistent with positioning ahead of a decision window rather than distribution. Simply put, the best has yet to come. 📈📈📈
